文献速递心力衰竭与心肌病瓣膜病与结构性心脏病

转甲状腺素蛋白淀粉样心肌病接受tafamidis治疗患者的心脏病恶化监测指标

Cardiac disease monitoring measures in patients with transthyretin amyloid cardiomyopathy treated with tafamidis.
PubMed 文献 · Heart · 2025-06-26

本研究在哥伦比亚大学纳入2018年后确诊并接受tafamidis治疗的转甲状腺素蛋白淀粉样心肌病(ATTR-CM)患者238例,将心脏病恶化(WCD)定义为NT-proBNP较基线升高>700 pg/mL且>30%或口服利尿剂强化或两者兼有。

要点

  • ATTR-CM患者接受tafamidis治疗1年内42%出现WCD。
  • WCD定义为NT-proBNP升高>700 pg/mL且>30%或口服利尿剂强化。
  • WCD与全因死亡和心血管住院风险升高独立相关。

核心结论

  • NT-proBNP升高和口服利尿剂强化可作为ATTR-CM患者接受tafamidis治疗期间心脏病恶化的标志物,并预测死亡和心血管住院风险。

研究设计与样本

  • 回顾性队列研究,纳入哥伦比亚大学2018年后确诊并接受tafamidis治疗的ATTR-CM患者238例。
  • 采用Kaplan-Meier曲线、Cox回归和竞争风险回归分析,校正年龄、基因型和基线NAC分期。

主要发现

  • 238例患者中100例(42%)在1年时出现WCD。

关键数值与推荐

  • WCD定义:NT-proBNP较基线升高>700 pg/mL且>30%,或口服利尿剂强化,或两者兼有。

临床怎么用

  • 在ATTR-CM患者接受tafamidis治疗随访中,可监测NT-proBNP变化和口服利尿剂使用情况以识别WCD。
  • 出现WCD的患者死亡和心血管住院风险较高,可能需要加强监测和干预。

局限性

  • 研究为单中心队列,样本量238例,结果外推需谨慎。
  • WCD定义基于NT-proBNP和利尿剂强化,尚未在指南中统一。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with transthyretin amyloid cardiomyopathy (ATTR-CM) often experience worsening cardiac disease (WCD) despite disease-modifying treatment. However, a strict definition is lacking. Recent studies have shown that N-terminal pro-B-natriuretic peptide (NT-proBNP increase), or intensification of oral diuretics, is associated with increased mortality risk. AIM: To describe the pattern of WCD at 1 year in patients with ATTR-CM on tafamidis and explore the association with mortality and cardiovascular (CV) hospitalisation. METHODS: Patients diagnosed with ATTR-CM at Columbia University after 2018 who were treated with tafamidis were enrolled in the study. WCD was defined as: increase in NT-proBNP >700 pg/mL and >30% from baseline or oral diuretic intensification (ODI) or both. Survival and CV hospitalisation risk analysis was performed using Kaplan-Meier curves, Cox regression and competing risk regression adjusted for age, genotype and disease severity by the National Amyloidosis Centre (NAC) stage. RESULTS: A total of 238 patients were enrolled, 100 (42%) of whom showed WCD at 1 year. WCD was associated with increased mortality risk (log rank, p<0.0001, HR=1.91 (1.10-3.32), p=0.023, after adjustment for age, genotype and baseline NAC stage). In competing risk analysis, WCD was associated with increased risk for CV-related hospitalisation (HR=1.8 (1.17-2.99, p=0.009)) after adjustment for age, genotype and baseline NAC stage. CONCLUSIONS: NT-proBNP increase and ODI can serve as markers of WCD and predict mortality and CV hospitalisations in a cohort of patients taking tafamidis.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Bampatsias D, Wardhere A, Zeldin L, et al. Cardiac disease monitoring measures in patients with transthyretin amyloid cardiomyopathy treated with tafamidis. Heart. 2025. PMID: 40122587. doi:10.1136/heartjnl-2024-324826

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。